Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
Most advanced or metastatic soft tissue sarcoma (STS) are unfortunately incurable, making the
preservation of the patient's quality of life a major goal, along with prolonging survival.
Age is not a criterion for not providing effective treatment, but the goals of treatment
change with age and must be integrated into the treatment decision. Elderly patients
prioritise a life free of dependency, preservation of their cognitive functions and quality
of life related to their state of health. They are therefore reluctant to receive a treatment
that does little to improve life expectancy at the cost of significant functional losses.
Patients aged 65 years and older account for one third of all patients with STS. In the
absence of dedicated recommendations, these elderly patients are currently receiving
doxorubicin-based chemotherapy as first-line treatment (as recommended for younger patients),
with a substantial risk of toxicity (especially cardiac). In this specific population,
previous studies have shown that oral cyclophosphamide seems to have a promising activity,
but also a very acceptable toxicity.
Thus, the GERICO study aims to compare standard doxorubicin chemotherapy with oral
cyclophosphamide for the treatment of elderly patients with STS.